Twitter timeline

Oncodesign reports positive results for its MNK1/2 program

December 5, 2017

  • MNK1 and MNK2 are kinases targeted in a major activation pathway for several cancers
  • The program has identified highly targeted inhibitor molecules and produced promising cellular results paving the way for lead optimization to begin

Download

Oncodesign announces positive results opening the way for the ALK1 program to advance to the lead optimization phase

November 15, 2017

  • Activin receptor-like kinase 1 (ALK1) is a target involved in angiogenesis with promising applications in cancer therapies
  • The program has identified highly targeted inhibitor molecules and produced promising cellular results paving the way for lead optimization to begin

Download